Catalog No.
DHE85301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
K5-5, CCR4, C-C CKR-4, CD194, CC-CKR-4, CCR-4, C-C chemokine receptor type 4, CMKBR4
Concentration
1.93 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P51679
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AMG-761, KW-0761, CAS: 1159266-37-1
Clone ID
Mogamulizumab
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial, PMID: 30100375
Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma, PMID: 30981611
Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas, PMID: 31648540
Mogamulizumab, PMID: 31643268
Mogamulizumab, PMID: 30272896
Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy, PMID: 32320304
Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma, PMID: 30799938
Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection, PMID: 32982179
Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study, PMID: 33091125
Mogamulizumab for the treatment of T-cell lymphoma, PMID: 28649848
Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review, PMID: 32449779
Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study, PMID: 25733162
Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy, PMID: 29414279
Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma, PMID: 33425472
A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors, PMID: 31455681
Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab, PMID: 31322628
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study, PMID: 32586937
Histopathologic Characterization of Mogamulizumab-associated Rash, PMID: 32976123
Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis, PMID: 32564395
Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma, PMID: 31018922
A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma, PMID: 31303060
Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma, PMID: 23110261
Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma, PMID: 30573506
Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas, PMID: 25496334
[Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint], PMID: 25948299
Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma, PMID: 28756726
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors, PMID: 31801624
Mogamulizumab Tops Standard of Care for CTCL, PMID: 29298770
Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential, PMID: 27247757
Mogamulizumab Plus EPOCH Therapy for Patients With Newly Diagnosed Aggressive Adult T-cell Leukemia/lymphoma, PMID: 32878812
Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment, PMID: 32362053
Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma, PMID: 32433748
Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy, PMID: 30894861
Radiation recall dermatitis induced by mogamulizumab, PMID: 31660660
Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all?, PMID: 31040231
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020, PMID: 32380458
Clinical significance of chemokine receptor antagonists, PMID: 31903790
Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma, PMID: 33022137
Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem, PMID: 31615932
Antibodies to watch in 2019, PMID: 30516432
Radiation-induced dermatitis after administration of mogamulizumab for adult T-cell leukaemia/lymphoma: a multi-institutional retrospective study, PMID: 30452692
Adult T-Cell Leukemia/Lymphoma, PMID: 28796966
Malignancy-associated pruritus, PMID: 26416212
CCR4 and its ligands: from bench to bedside, PMID: 25087232
Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma, PMID: 33158772
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome, PMID: 31366601
Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice, PMID: 28152225
How I treat adult T-cell leukemia/lymphoma, PMID: 33075812
Exposure-Response Analysis for Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma, PMID: 31840837
Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical Response, PMID: 31141114
For research use only. Not for human or drug use.
